Merck & Co., Inc. MRK

148.78 0.80 0.54% as of 25 Sep
Market cap
$365.4B
P/E
119×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years

Merck & Co., Inc. (MRK) Debt to equity

Merck & Co., Inc.'s debt to equity at the end of the quarter to 30 June 2026 was 1.2×, up 0.3× from fiscal 2025 (0.9×). Over the past ten years it has ranged from 0.5× (fiscal 2015) to 1.0× (fiscal 2020); the current reading is higher than 82% of that period. That is above the Drug Manufacturers General industry median of 0.6× and above the Healthcare sector median of 0.0×.

Debt to equity, annual

Annual

Period Debt to equity Change
FY2025 0.9× 19.44%
FY2024 0.7× (16.96%)
FY2023 0.9× 43.41%
FY2022 0.6× (22.20%)
FY2021 0.8× (19.64%)
FY2020 1.0× 14.17%
FY2019 0.9× 18.68%
FY2018 0.7× 19.28%
FY2017 0.6× 2.57%
FY2016 0.6× 13.13%

Quarterly

Period Debt to equity Change
Jun 2026 1.2× 19.73%
Mar 2026 1.0× 14.48%
Dec 2025 0.9× 15.29%
Sep 2025 0.8× 11.21%
42 more quarters

Against its own ten years

Low 0.5× High 1.0×
Ten-year median 0.7×
Current reading's percentile 82

Debt to equity against peers

Company Debt to equity
ABBV AbbVie Inc. compare −12.0×
JNJ Johnson & Johnson compare 0.4×
AZN AstraZeneca PLC compare 0.6×
NVO Novo Nordisk A/S compare 0.6×
PFE Pfizer Inc. compare 0.7×
NVS Novartis AG compare 1.1×
MRK Merck & Co., Inc. 1.2×
GILD Gilead Sciences, Inc. compare 2.2×
AMGN Amgen Inc. compare 4.9×
Drug Manufacturers General industry median 0.6×
Healthcare sector median 0.0×
Market median 0.2×

What Debt to equity is

Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.

(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)

The full definition of Debt to equity →

More on MRK